Abstract:Objectives: The mammalian target of Rapamycin (mTOR) is a metabolic master regulator of both innate and adaptive immunity; however, its exact role in stromal cell biology is unknown. In this study we explored the role of the mTOR pathway on Rheumatoid Arthritis synovial fibroblast (RASF) metabolism and activation and determined if crosstalk with the Hippo-YAP pathway mediates their effects. Methods: Primary RA synovial fibroblasts (RASF) were cultured with TNFα alone or in combination with the mTOR inhibitor Rapamycin or YAP inhibitor Verteporfin. Chemokine production, matrix metalloproteinase (MMP) production, and adhesion marker expression were quantified by real-time PCR, ELISA, and/or Flow Cytometry. Invasion assays were performed using Transwell invasion chambers, while wound repair assays were used to assess RASF migration. Cellular bioenergetics was assessed using the Seahorse XFe96 Analyzer. Key metabolic genes (GLUT-1, HK2, G6PD) were measured using real-time PCR. Reanalysis of RNA-Seq analysis was performed on RA (n = 151) and healthy control (HC) (n = 28) synovial tissue biopsies to detect differential gene and pathway expression. The expression of YAP was measured by Western Blot. Results: Transcriptomic analysis of healthy donor and RA synovial tissue revealed dysregulated expression of several key components of the mTOR pathway in RA. Moreover, the expression of phospho-ribosomal protein S6 (pS6), the major downstream target of mTOR is specifically increased in RA synovial fibroblasts compared to healthy tissue. In the presence of TNFα, RASF display heightened phosphorylation of S6 and are responsive to mTOR inhibition via Rapamycin. Rapamycin effectively alters RASF cellular bioenergetics by inhibiting glycolysis and the expression of rate limiting glycolytic enzymes. Furthermore, we demonstrate a key role for mTOR signaling in uniquely mediating RASF migratory and invasive mechanisms, which are significantly abrogated in the presence of Rapamycin. Finally, we report a significant upregulation in several genes involved in the Hippo-YAP pathway in RA synovial tissue, which are predicted to converge with the mTOR pathway. We demonstrate crosstalk between the mTOR and YAP pathways in mediating RASF invasive mechanism whereby Rapamycin significantly abrogates YAP expression and YAP inhibition significantly inhibits RASF invasiveness. Conclusion: mTOR drives pathogenic mechanisms in RASF an effect which is in part mediated via crosstalk with the Hippo-YAP pathway.

mTOR pathway activation in large vessel vasculitis

mTOR signalling controls the formation of smooth muscle cell-derived luminal myofibroblasts during vasculitis

Proteomic profiling of the large vessel vasculitis spectrum identifies shared signatures of innate immune activation and stromal remodelling

Vasculitogenic T Cells in Large Vessel Vasculitis

Current evidence on the role of fibroblasts in large-vessel vasculitides: From pathogenesis to therapeutics

The mammalian target of rapamycin contributes to synovial fibroblast pathogenicity in rheumatoid arthritis

Mammalian Target of Rapamycin as the Therapeutic Target of Vascular Proliferative Diseases: Past, Present, and Future

The Contribution of Innate Immunity in Large-Vessel Vasculitis: Detangling New Pathomechanisms beyond the Onset of Vascular Inflammation

Glomerular mTORC1 activation was associated with podocytes to endothelial cells communication in lupus nephritis

The Th17 Pathway in Vascular Inflammation: Culprit or Consort?

Pathogenic role of monocytes/macrophages in large vessel vasculitis

Renal Mtorc1 Activation is Associated with Disease Activity and Prognosis in Lupus Nephritis.

Pros and cons of TNF inhibitors and tocilizumab in the treatment of large-vessel vasculitis

Therapeutic mTOR blockade in systemic autoimmunity: Implications for antiviral immunity and extension of lifespan

A Novel Molecular Mechanism of Vascular Fibrosis in Takayasu Arteritis: Macrophage-Derived GPNMB Promoting Adventitial Fibroblast Extracellular Matrix Production in the Aorta.

Hyperactive mTORC1 in lung mesenchyme induces endothelial cell dysfunction and pulmonary vascular remodeling

Mtor Signaling: A Pivotal Player in Treg Cell Dysfunction in Systemic Lupus Erythematosus.

Pivotal Role of mTOR in Non-Skin Manifestations of Psoriasis

Dynamics of scFv-targeted VAP2 correlating with IL-16, MIF and IL-1Ra in ANCA-associated vasculitis

Neointimal myofibroblasts contribute to maintaining Th1/Tc1 and Th17/Tc17 inflammation in giant cell arteritis

Therapeutic targeting of chronic kidney disease-associated DAMPs differentially contributing to vascular pathology